Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of almonertinib + bevacizumab as first-line treatment for EGFR-mutant non-squamous non-small cell lung cancer with brain metastases
ChiCTR2200060886Phase 2Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib and bevacizumab in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Recommended Phase II Dose and Intracranial Progression-free Survival. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
almonertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2200060886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060886.